The estimated Net Worth of Manoj Maniar is at least $662 mil dollars as of 30 June 2016. Manoj Maniar owns over 50 units of Onconova Therapeutics Inc stock worth over $50 and over the last 9 years he sold ONTX stock worth over $0. In addition, he makes $662,385 as Senior Vice President - Product Development at Onconova Therapeutics Inc.
Manoj has made over 1 trades of the Onconova Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 50 units of ONTX stock worth $325 on 30 June 2016.
The largest trade he's ever made was exercising 50 units of Onconova Therapeutics Inc stock on 30 June 2016 worth over $325. On average, Manoj trades about 5 units every 0 days since 2015. As of 30 June 2016 he still owns at least 50 units of Onconova Therapeutics Inc stock.
You can see the complete history of Manoj Maniar stock trades at the bottom of the page.
Dr. Manoj Maniar, Ph.D., serves as Senior Vice President - Product Development of Onconova Therapeutics, Inc. Prior to joining the Company, Dr. Maniar was with SRI International, Inc., a nonprofit research institute, where he served as Senior Director, Formulations and Drug Delivery. Dr. Maniar received his B.S. in Pharmacy from Bombay College of Pharmacy and his Ph.D. in Pharmaceutics from the University of Connecticut.
As the Senior Vice President - Product Development of Onconova Therapeutics Inc, the total compensation of Manoj Maniar at Onconova Therapeutics Inc is $662,385. There are 1 executives at Onconova Therapeutics Inc getting paid more, with Dr. Steven M. Fruchtman having the highest compensation of $865,438.
Manoj Maniar is 52, he's been the Senior Vice President - Product Development of Onconova Therapeutics Inc since 2005. There are 9 older and 2 younger executives at Onconova Therapeutics Inc. The oldest executive at Onconova Therapeutics Inc is Henry Bienen, 77, who is the Director.
Manoj's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC., 375 PHEASANT RUN, NEWTOWN, PA, 18940.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683, eCapital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: